Genescience Pharmaceuticals Co. Ltd. has identified fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, osteochondrodysplasia and achondroplasia.

Quantx Biosciences US Inc. has described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged compounds acting as Toll-like receptor 7 (TLR7) and TLR8 agonists reported to be useful for the treatment of cancer.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized sodium-bile acid cotransporter (SLC10A1; NTCP) inhibitors reported to be useful for the treatment of cardiovascular, fatty acid oxidation, liver and gastrointestinal disorders.

Insilico Medicine Inc. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune and inflammatory disorders.

Shanghai Institute of Organic Chemistry has described leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory disorders, Parkinson’s disease and Alzheimer’s disease, among others.

Magicbullet Therapeutics Inc. has divulged protein kinase inhibitors reported to be useful for the treatment of cancer.

Lento Bio Inc. has synthesized cysteine derivatives reported to be useful for the treatment of presbyopia. An exemplified compound (Cpd in row 4 in tbl1 pg 20, claim 18) decreased in lens stiffness in C57BL/6 mice (at 20 mM; as eye drops).

Iregene Therapeutics (Suzhou) Co. Ltd. has identified pyrazolecarbonyl piperazinone compounds acting as bone morphogenetic protein receptor type-1B (BMPR1B) inhibitors reported to be useful for the treatment of cancer and pulmonary hypertension.

Circle Pharma Inc. has disclosed cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer.